Beverly Hills Private Wealth LLC Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

Beverly Hills Private Wealth LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,203 shares of the company's stock after buying an additional 7,048 shares during the quarter. Beverly Hills Private Wealth LLC's holdings in Novo Nordisk A/S were worth $3,000,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL raised its position in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares in the last quarter. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter worth about $27,000. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $29,000. Finally, Transce3nd LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $33,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 0.2%

NVO stock traded up $0.14 during mid-day trading on Monday, reaching $69.31. The company had a trading volume of 7,307,060 shares, compared to its average volume of 7,260,984. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The company has a market capitalization of $309.47 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The firm has a 50 day moving average of $69.96 and a 200 day moving average of $75.52. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.